Byrd Richard
Known title: EVP & President InterventionalCIK: 0001945298
Associated companies
Transaction History
| BDX | ▲ Buy | Grant | 6,447 | $0 | 11/26/2025 | View on chart |
| BDX | ▲ Buy | Grant | 2,385 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,719 | $0 | 11/26/2025 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 216 | $0 | 9/1/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 459 | $106K | 3/18/2025 | View on chart |
| BDX | ▼ Sell | Open Market | 1,940 | $436K | 3/12/2025 | View on chart |
| BDX | ▲ Buy | Grant | 2,220 | $0 | 11/26/2024 | View on chart |
| BDX | ▲ Buy | Grant | 2,275 | $0 | 11/26/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,204 | $0 | 11/26/2024 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 216 | $0 | 9/1/2024 | View on chart |
| BDX | ▼ Sell | Open Market | 2,156 | $514K | 11/28/2023 | View on chart |
| BDX | ▲ Buy | Grant | 1,455 | $0 | 11/26/2023 | View on chart |
| BDX | ▲ Buy | Grant | 2,886 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 1,509 | $0 | 11/26/2023 | View on chart |
| BDX | ▼ Sell | Open Market | 459 | $126K | 9/5/2023 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 216 | $0 | 9/1/2023 | View on chart |
| BDX | ▼ Sell | Open Market | 1,421 | $353K | 2/3/2023 | View on chart |
| BDX | ▲ Buy | Grant | 1,226 | $0 | 11/26/2022 | View on chart |
| BDX | ▲ Buy | Grant | 1,275 | $0 | 11/26/2022 | View on chart |
| BDX | ▼ Sell | Tax Withholding | 711 | $0 | 11/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.